2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph.
暂无分享,去创建一个
[1] Eoin Coakley,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.
[2] J. Pawlotsky. Hepatitis C virus: from discovery to eradication in 40 years? , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] Libin Rong,et al. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. , 2010, Critical reviews in immunology.
[4] C. Schlatter,et al. Genotoxicity of aniline derivatives in various short-term tests. , 1989, Mutation research.
[5] Thomas Berg,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.
[6] M. Poss,et al. The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase. , 2011, Organic & biomolecular chemistry.
[7] I. Melnikova. Hepatitis C therapies , 2008, Nature Reviews Drug Discovery.
[8] Alan S. Perelson,et al. Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model , 2013, PLoS Comput. Biol..
[9] R. Bartenschlager,et al. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. , 1998, Virology.
[10] A Tramontano,et al. Substrate Specificity of the Hepatitis C Virus Serine Protease NS3* , 1997, The Journal of Biological Chemistry.
[11] J. Kort,et al. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection , 2015, Antimicrobial Agents and Chemotherapy.
[12] S. Lewin,et al. The end of AIDS: HIV infection as a chronic disease , 2013, The Lancet.
[13] D. Lamarre,et al. Solution Structure of Substrate-based Ligands When Bound to Hepatitis C Virus NS3 Protease Domain* , 1999, The Journal of Biological Chemistry.
[14] N. Meanwell,et al. Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes. , 2011, ACS medicinal chemistry letters.
[15] U. Koch,et al. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. , 2000, Biochemistry.
[16] W. Windsor,et al. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides , 1997, Journal of virology.
[17] J. Wells,et al. Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection , 2016, Expert review of gastroenterology & hepatology.
[18] L. Hamann,et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. , 2014, Journal of medicinal chemistry.
[19] Y. Karino,et al. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms , 2015, Advances in Therapy.
[20] S. Kottilil,et al. Treatment of hepatitis C: a systematic review. , 2014, JAMA.
[21] K. Reddy,et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.
[22] Ross J. Harris,et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. , 2014, Journal of hepatology.
[23] R. Bartenschlager. Hepatitis C virus replicons: potential role for drug development , 2002, Nature Reviews Drug Discovery.
[24] B. Autran,et al. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.
[25] C. Stedman,et al. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. , 2016, Gastroenterology.
[26] D. Rein,et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[27] M. Nassal. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.
[28] Connie Celum,et al. HIV infection: epidemiology, pathogenesis, treatment, and prevention , 2014, The Lancet.
[29] A. Neumann,et al. Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations , 1998, Journal of Virology.
[30] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[31] M. Gale,et al. Regulation of hepatic innate immunity by hepatitis C virus , 2013, Nature Medicine.
[32] R. Chung. A watershed moment in the treatment of hepatitis C. , 2012, The New England journal of medicine.
[33] Paul L. Martin,et al. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C , 2016, Expert opinion on drug safety.
[34] Tom Chu,et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial , 2010, The Lancet.
[35] Kenji Ikeda,et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. , 2013, Journal of hepatology.
[36] M. Houghton. Discovery of the hepatitis C virus , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[37] P. Stanley,et al. 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase. , 1998, Journal of medicinal chemistry.
[38] Libin Rong,et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.
[39] J J Baldwin,et al. Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.
[40] B. Snider,et al. Manganese(III)-based oxidative free-radical cyclization of unsaturated .beta.-keto esters, 1,3-diketones, and malonate diesters , 1990 .
[41] C. Rice,et al. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes , 1993, Journal of virology.
[42] S. Naggie,et al. Successes and Challenges on the Road to Cure Hepatitis C , 2015, PLoS pathogens.
[43] M. St. Claire,et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Bartenschlager,et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.
[45] J. Rockstroh,et al. HIV and the body: a review of multidisciplinary management , 2010, HIV medicine.
[46] M. Mondelli,et al. Clinical significance of hepatitis C virus genotypes. , 1999, Journal of hepatology.
[47] K. Koehler,et al. A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. , 2002, Bioorganic & medicinal chemistry letters.
[48] H. Parge,et al. The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.
[49] J. Lemm,et al. Potency and Resistance Analysis of Hepatitis C Virus NS5B Polymerase Inhibitor BMS-791325 on All Major Genotypes , 2014, Antimicrobial Agents and Chemotherapy.
[50] A. Lok,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.
[51] J. Hoofnagle,et al. From non-A, non-B hepatitis to hepatitis C virus cure. , 2015, Journal of hepatology.
[52] K. Hasegawa,et al. Daclatasvir and asunaprevir for recurrent hepatitis C following living donor liver transplantation with HIV co‐infection , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.
[53] F. Zoulim,et al. Antiviral therapies and prospects for a cure of chronic hepatitis B. , 2015, Cold Spring Harbor perspectives in medicine.
[54] J. Pawlotsky. Hepatitis C virus (HCV) NS5A protein: role in HCV replication and resistance to interferon‐α , 1999, Journal of viral hepatitis.
[55] F. G. Njoroge,et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. , 2008, Accounts of chemical research.
[56] R. Bartenschlager,et al. On the history of hepatitis C virus cell culture systems. , 2014, Journal of medicinal chemistry.
[57] R. McGuire,et al. Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments. , 1996, Journal of medicinal chemistry.
[58] D. Dieterich,et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.
[59] T. Tellinghuisen,et al. Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein , 2008, PLoS pathogens.
[60] Y. Shu,et al. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. , 2015, Journal of pharmaceutical sciences.
[61] S. Raybuck,et al. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. , 1997, Biochemistry.
[62] P. Bonneau,et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. , 2003, Angewandte Chemie.
[63] S. LaPlante,et al. Transferred 13C T1 Relaxation at Natural Isotopic Abundance: A Practical Method for Determining Site-Specific Changes in Ligand Flexibility upon Binding to a Macromolecule , 2000 .
[64] R. Bartenschlager,et al. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity , 1997, Journal of virology.
[65] T. Liang,et al. Current and future therapies for hepatitis C virus infection. , 2013, The New England journal of medicine.
[66] V. Arora,et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor. , 2014, Journal of pharmaceutical sciences.
[67] M. Shiffman,et al. What future for ribavirin? , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[68] F. Chisari,et al. Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.
[69] Brad J. Wood,et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study , 2015, The Lancet.
[70] M. Bolli,et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. , 2010, Journal of medicinal chemistry.
[71] Alan S. Perelson,et al. Modelling hepatitis C therapy—predicting effects of treatment , 2015, Nature Reviews Gastroenterology &Hepatology.
[72] P. Barr,et al. Genetic organization and diversity of the hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[73] F. Zoulim,et al. Global strategies are required to cure and eliminate HBV infection , 2016, Nature Reviews Gastroenterology and Hepatology.
[74] Suresh,et al. Recent Pharmacological Developments on Rhodanines and 2,4-Thiazolidinediones , 2013, International journal of medicinal chemistry.
[75] Jerome Wielens,et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA , 2014, Scientific Reports.
[76] T. Asselah,et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial , 2015, The Lancet.
[77] P. Selwyn,et al. Complications of HIV infection: a systems-based approach. , 2011, American family physician.
[78] J. Tice,et al. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. , 2016, JAMA internal medicine.
[79] T. Liang,et al. The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C , 2012, Antiviral chemistry & chemotherapy.
[80] J. Arnold,et al. Hepatitis C Virus Nonstructural Protein 5A (NS5A) Is an RNA-binding Protein* , 2005, Journal of Biological Chemistry.
[81] Alan S. Perelson,et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .
[82] C. Rice,et al. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase , 2005, Nature.
[83] A. J. T. te Velthuis. Common and unique features of viral RNA-dependent polymerases , 2014, Cellular and Molecular Life Sciences.
[84] C. Cameron,et al. Correlation between NS5A Dimerization and Hepatitis C Virus Replication* , 2012, The Journal of Biological Chemistry.
[85] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[86] N. Meanwell,et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032) , 2012, Antimicrobial Agents and Chemotherapy.
[87] J. Wong,et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.
[88] P. Thuluvath,et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. , 2014, Journal of hepatology.
[89] Substituent effects on the in vitro and in vivo genotoxicity of 4-aminobiphenyl and 4-aminostilbene derivatives. , 1994, Mutation research.
[90] J. Ward. Hepatitis C virus: The 25‐year journey from discovery to cure , 2014, Hepatology.
[91] R. De Francesco,et al. Inhibition of the Hepatitis C Virus NS3/4A Protease , 2000, The Journal of Biological Chemistry.
[92] P. Thuluvath,et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection , 2015, Annals of Internal Medicine.
[93] J. Erickson,et al. Hydrogen Bond Donor Properties of the Difluoromethyl Group , 1995 .
[94] Roger D. Kouyos,et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance , 2011, Proceedings of the National Academy of Sciences.
[95] P. Tebas,et al. Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection , 2014, Antimicrobial Agents and Chemotherapy.
[96] B. Samuelsson,et al. Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals. , 2003, Bioorganic & medicinal chemistry.
[97] M. Hickey,et al. Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus , 2009, Journal of Virology.
[98] E. Gane. Hepatitis C beware—the end is nigh , 2014, The Lancet.
[99] S. Venkatraman. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. , 2012, Trends in pharmacological sciences.
[100] C. Brochu,et al. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds. , 2006, Bioorganic & medicinal chemistry letters.
[101] Eva Herrmann,et al. New kinetic models for the hepatitis C virus , 2005, Hepatology.
[102] D. Samuel,et al. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[103] E. Schiff,et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence , 2016, Hepatology.
[104] B. Rehermann,et al. Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.
[105] G. Esmat,et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.
[106] Alan S. Perelson,et al. Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus , 2010, Science Translational Medicine.
[107] J. Glenn,et al. Mechanisms of HCV survival in the host , 2009, Nature Reviews Gastroenterology &Hepatology.
[108] N. Meanwell,et al. Identification of Hepatitis C Virus NS5A Inhibitors , 2009, Journal of Virology.
[109] Masahiro Irie,et al. Diarylethenes for Memories and Switches. , 2000, Chemical reviews.
[110] Yogesh Sabnis,et al. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. , 2007, Bioorganic & medicinal chemistry.
[111] Kenji Ikeda,et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. , 2013, Journal of hepatology.
[112] M. Murcko,et al. Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide , 1996, Cell.
[113] G. Borgia,et al. Beclabuvir for the treatment of hepatitis C , 2015, Expert opinion on investigational drugs.
[114] G. Dore,et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. , 2015, JAMA.
[115] Weiying Yang,et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: , 2006, Journal of medicinal chemistry.
[116] S. Horner,et al. Activation and evasion of antiviral innate immunity by hepatitis C virus. , 2014, Journal of molecular biology.
[117] Cindy L. Zoellner,et al. Role of ribavirin in HCV treatment response: now and in the future , 2010, Expert opinion on pharmacotherapy.
[118] T. Pilot‐Matias,et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.
[119] M. Houghton,et al. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. , 1993, Biochemical and biophysical research communications.
[120] Raymond T Chung,et al. Curing chronic hepatitis C--the arc of a medical triumph. , 2014, The New England journal of medicine.
[121] A. Kwong. The HCV Revolution Did Not Happen Overnight , 2014, ACS Medicinal Chemistry Letters.
[122] J. Duan,et al. From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons. , 2011, Bioorganic & medicinal chemistry letters.
[123] A. Azvolinsky. Industry chases pan-genotypic and shorter HCV treatments , 2015, Nature Biotechnology.
[124] A. Good,et al. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. , 2014, Journal of medicinal chemistry.
[125] Marawan Ahmed,et al. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. , 2015, Drug discovery today.
[126] D. Bonnet,et al. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection , 2016, Expert opinion on pharmacotherapy.
[127] N. Meanwell,et al. Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase , 2014, Antimicrobial Agents and Chemotherapy.
[128] G. Dore,et al. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[129] D. Wyles,et al. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. , 2013, The Journal of infectious diseases.
[130] T. Asselah,et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.
[131] S. Wilhelm,et al. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir , 2016, Expert review of clinical pharmacology.
[132] U. Siebert,et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality , 2009, BMC public health.
[133] A. Kwong,et al. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. , 2006, Infectious disorders drug targets.
[134] Michael Rowley,et al. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. , 2005, Journal of medicinal chemistry.
[135] T. Brown,et al. Management of the metabolic effects of HIV and HIV drugs , 2012, Nature Reviews Endocrinology.
[136] N. Kato,et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus , 1993, Journal of virology.
[137] Ronald Pruitt,et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. , 2016, Journal of hepatology.
[138] H. Conjeevaram. Continued progress against hepatitis C infection. , 2015, JAMA.
[139] E. Roda,et al. Ribavirin for chronic hepatitis C: and the mystery goes on. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[140] Catrin Hasselgren,et al. Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2. , 2011, Journal of the American Chemical Society.
[141] C. Passaes,et al. HIV cure research: advances and prospects. , 2014, Virology.
[142] I. Jacobson,et al. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. , 2012, Antiviral therapy.
[143] P. Sax,et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.
[144] Min Gao,et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.
[145] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[146] P. Belperio,et al. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort , 2014, Alimentary pharmacology & therapeutics.
[147] Carl T. Bergstrom,et al. Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus. , 2011, Bioorganic & medicinal chemistry letters.
[148] J. Janc,et al. Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease. , 2001, Bioorganic & medicinal chemistry letters.
[149] E. Verdin,et al. Understanding HIV latency: the road to an HIV cure. , 2015, Annual review of medicine.
[150] C. Cameron,et al. Hepatitis C Virus Nonstructural Protein 5A: Biochemical Characterization of a Novel Structural Class of RNA-Binding Proteins , 2010, Journal of Virology.
[151] Wonsuk Chang,et al. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. , 2012, Journal of medicinal chemistry.
[152] E. Åkerblom,et al. Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region. , 2014, ACS medicinal chemistry letters.
[153] R. M. Owen,et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.
[154] John E Leet,et al. HPLC Biogram Analysis , 2015, Journal of biomolecular screening.
[155] A. Good,et al. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons. , 2014, Journal of medicinal chemistry.
[156] M. Levrero,et al. Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.
[157] D. Wyles,et al. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy , 2014, Journal of viral hepatitis.
[158] V. Cunningham,et al. Hydrolysis of oleylanilide in the rat , 1983, Archives of Toxicology.
[159] A. Spivak,et al. HIV-1 Eradication: Early Trials (and Tribulations). , 2016, Trends in molecular medicine.
[160] Ralf Bartenschlager,et al. Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly , 2008, PLoS pathogens.
[161] R. Cortese,et al. Product inhibition of the hepatitis C virus NS3 protease. , 1998, Biochemistry.
[162] M. Thursz,et al. HCV transmission in industrialized countries and resource-constrained areas , 2014, Nature Reviews Gastroenterology &Hepatology.
[163] Xin Huang,et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.
[164] R. Bartenschlager. The hepatitis C virus replicon system: from basic research to clinical application. , 2005, Journal of hepatology.
[165] H. Razavi,et al. Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States , 2013, Hepatology.
[166] K. Lawson,et al. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta‐analysis , 2014, Journal of clinical pharmacy and therapeutics.
[167] Nicholas A Meanwell,et al. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. , 2016, Chemical research in toxicology.
[168] Alexander R. Pico,et al. From Scientific Discovery to Cures: Bright Stars within a Galaxy , 2015, Cell.
[169] A. Lok,et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. , 2014, Journal of hepatology.
[170] C. Rice,et al. Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo , 2000, Journal of Virology.
[171] B. Imperiali,et al. Extended binding inhibitors of chymotrypsin that interact with leaving group subsites S1'-S3'. , 1987, Biochemistry.
[172] C. Hézode,et al. Ideal oral combinations to eradicate HCV: The role of ribavirin. , 2016, Journal of hepatology.
[173] C. Pye,et al. The functional group on (E)-4,4'-disubstituted stilbenes influences toxicity and antioxidative activity in differentiated PC-12 cells. , 2013, Bioorganic & medicinal chemistry letters.
[174] A. Folgori,et al. Biochemical and Immunologic Properties of the Nonstructural Proteins of the Hepatitis C Virus: Implications for Development of Antiviral Agents and Vaccines , 2000, Seminars in liver disease.
[175] Charles M. Rice,et al. The ins and outs of hepatitis C virus entry and assembly , 2013, Nature Reviews Microbiology.
[176] F. Lichtenberg. Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-Income Countries, 2000-2009 , 2012 .
[177] T. Gojobori,et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[178] Alan S. Perelson,et al. Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate , 2012, PLoS pathogens.
[179] M. Bassetti,et al. Impact of new treatment options for hepatitis C virus infection in liver transplantation. , 2015, World journal of gastroenterology.
[180] Chong-Hwan Chang,et al. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. , 2014, Journal of medicinal chemistry.
[181] F. Penin,et al. From Structure to Function: New Insights into Hepatitis C Virus RNA Replication* , 2006, Journal of Biological Chemistry.
[182] D. Nelson,et al. The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[183] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[184] G. Keating,et al. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. , 2003, Drugs.
[185] M. Polis,et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. , 2015, The Lancet. Infectious diseases.
[186] A. Verma,et al. 4-Thiazolidinones: the advances continue…. , 2014, European journal of medicinal chemistry.
[187] N. Meanwell. Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.
[188] V. de Lédinghen,et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. , 2015, Gastroenterology.
[189] Z. Younossi,et al. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment , 2015, Therapeutic advances in gastroenterology.
[190] R. Fontana,et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[191] A. Alberti,et al. Literature review of the distribution of hepatitis C virus genotypes across Europe , 2016, Journal of medical virology.
[192] Tara L. Kieffer,et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. , 2008, The Journal of infectious diseases.
[193] T. Sugimura,et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[194] K. Chayama,et al. Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.
[195] M. Gao,et al. Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir , 2013, Antimicrobial Agents and Chemotherapy.
[196] Sanjeev Arora,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[197] R. De Francesco,et al. In Vitro Activity of Hepatitis C Virus Protease NS3 Purified from Recombinant Baculovirus-infected Sf9 Cells (*) , 1996, The Journal of Biological Chemistry.
[198] Rachel S Tocco,et al. Public health impact of antiviral therapy for hepatitis C in the United States , 2009, Hepatology.
[199] G. Gerken,et al. Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant , 2015, Digestion.
[200] Ara Ak,et al. New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection , 2015 .
[201] N. Green,et al. Cell-based assays to identify inhibitors of viral disease , 2008, Expert opinion on drug discovery.
[202] R. Francesco,et al. Identification and properties of the RNA‐dependent RNA polymerase of hepatitis C virus. , 1996, The EMBO journal.
[203] J. Gerstoft,et al. Grazoprevir and elbasvir: a second-generation protease inhibitor and a second-generation NS5A inhibitor in a combination regimen for treatment of chronic hepatitis C , 2015 .
[204] J. Silver,et al. Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .
[205] N. Meanwell,et al. A practical and efficient synthesis of 6-carboalkoxy-13-cycloalkyl-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives , 2014 .
[206] Min Gao,et al. Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 , 2011, Hepatology.
[207] Min Gao,et al. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A , 2015, Nature.
[208] Michael A. Smith,et al. The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy , 2015, Expert opinion on drug safety.
[209] F. Chisari,et al. Stealth and Cunning: Hepatitis B and Hepatitis C Viruses , 2005, Journal of Virology.
[210] R. Monina Klevens,et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.
[211] P. Maher,et al. Back to the future with phenotypic screening. , 2014, ACS chemical neuroscience.
[212] N. Meanwell,et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. , 2014, Journal of medicinal chemistry.
[213] C. Cameron,et al. Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target* , 2010, The Journal of Biological Chemistry.
[214] B. Beno,et al. Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase , 2014, The Journal of Biological Chemistry.
[215] E. Deeks. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection , 2015, Drugs.
[216] J. Dumortier,et al. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[217] C. Trépo,et al. A brief history of hepatitis milestones , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[218] S. Griffin,et al. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. , 2009, The Journal of general virology.
[219] S. Zeuzem,et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[220] Tara L. Kieffer,et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.
[221] R. Gish. Treating HCV with ribavirin analogues and ribavirin-like molecules. , 2006, The Journal of antimicrobial chemotherapy.
[222] Vincent Zoete,et al. A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules , 2016, ChemMedChem.
[223] W. Kraft,et al. Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C , 2012, Antimicrobial Agents and Chemotherapy.
[224] C. Sheridan. FDA approvals usher in the post-interferon era in HCV , 2014, Nature Biotechnology.
[225] M. Imamura,et al. Genetics of IL28B and HCV—response to infection and treatment , 2012, Nature Reviews Gastroenterology &Hepatology.
[226] S. Keam,et al. Peginterferon-α-2a (40 kD) Plus Ribavirin , 2012, Drugs.
[227] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[228] R. Poole. Daclatasvir + Asunaprevir: First Global Approval , 2014, Drugs.
[229] N. Meanwell,et al. A facile construction of 4-hydroxymethylbenzisothiazolone-1,1-dioxide , 1998 .
[230] Robert Merényi,et al. The captodative effect , 1985 .
[231] U. Protzer,et al. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. , 2016, Journal of hepatology.
[232] G. Missale,et al. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis , 2015, The Pharmacogenomics Journal.
[233] Robert Herring,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.
[234] A. Good,et al. HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives. , 2013, Bioorganic & medicinal chemistry letters.
[235] Robert M. Stroud,et al. Design of potent selective zinc-mediated serine protease inhibitors , 1998, Nature.
[236] M. Katharine Holloway,et al. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. , 2008, Journal of the American Chemical Society.
[237] Pravin Chaturvedi,et al. Design principles for orally bioavailable drugs , 1996 .
[238] Y. Tsantrizos. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061—From the NMR tube to the clinic , 2004, Biopolymers.
[239] O. Yokosuka,et al. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan , 2016, International journal of medical sciences.
[240] M. Nguyen,et al. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1 , 2015, Expert opinion on pharmacotherapy.
[241] Y. Tsantrizos. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. , 2008, Accounts of chemical research.
[242] Yogesh Sabnis,et al. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors. , 2007, Bioorganic & medicinal chemistry.
[243] J. Janc,et al. Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. , 2002, Bioorganic & medicinal chemistry letters.
[244] R. Fontana,et al. Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[245] J. Janc,et al. A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by Zinc(II). , 2000, Biochemistry.
[246] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[247] N. Meanwell,et al. Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures , 2011, Antimicrobial Agents and Chemotherapy.
[248] A. Perelson,et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128) , 2012, Hepatology.
[249] Qi Gao,et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. , 2014, Journal of medicinal chemistry.
[250] N. Zein. Clinical Significance of Hepatitis C Virus Genotypes , 2000, Clinical Microbiology Reviews.
[251] T. Ayer,et al. Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals , 2016, Hepatology.
[252] N. Utay,et al. A new era of therapy for hepatitis C virus infection , 2015, Current opinion in infectious diseases.
[253] N. Meanwell,et al. HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides. , 2012, Bioorganic & medicinal chemistry letters.
[254] F. Penin,et al. Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus , 2011, Journal of viral hepatitis.
[255] J. Pawlotsky. Pathophysiology of hepatitis C virus infection and related liver disease. , 2004, Trends in microbiology.
[256] Sebastian Lambert,et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors , 2014, Protein science : a publication of the Protein Society.
[257] N. Meanwell,et al. A synthesis of 4-thiomethylbenzisothiazolone-1,1-dioxide using HDPT , 1998 .
[258] G. Ippolito,et al. Is hepatitis C virus eradication around the corner only 25 years after its discovery? , 2015, International journal of antimicrobial agents.
[259] Sammy Saab,et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. , 2014, JAMA internal medicine.
[260] Constantine Kosmidis,et al. The photochemical cis-trans isomerization of free stilbene molecules follows a hula-twist pathway. , 2004, Angewandte Chemie.
[261] D. Pratt,et al. Advances in radical-trapping antioxidant chemistry in the 21st century: a kinetics and mechanisms perspective. , 2014, Chemical reviews.
[262] B. Snider. Manganese(III)-Based Oxidative Free-Radical Cyclizations. , 1996, Chemical reviews.
[263] B. Katz,et al. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases. , 2000, Journal of molecular biology.
[264] G. Keating. Elbasvir/Grazoprevir: First Global Approval , 2016, Drugs.
[265] S. Holmberg,et al. Evolving epidemiology of hepatitis C virus in the United States. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[266] Anna Persson,et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.
[267] Anushree Chatterjee,et al. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? , 2012, Antiviral therapy.
[268] P. Thuluvath,et al. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study , 2015, Hepatology.
[269] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[270] Hao Jiang,et al. A validated LC-MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[271] M. Houghton. The long and winding road leading to the identification of the hepatitis C virus. , 2009, Journal of hepatology.
[272] N. Meanwell,et al. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity. , 2014, Journal of medicinal chemistry.
[273] R. Marinho,et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.
[274] S. Holmberg,et al. Toward a more accurate estimate of the prevalence of hepatitis C in the United States , 2015, Hepatology.
[275] M. Sinz. Pregnane X Receptor: Prediction and Attenuation of Human CYP3A4 Enzyme Induction and Drug–Drug Interactions , 2008 .
[276] Guangdi Li,et al. Approved Antiviral Drugs over the Past 50 Years , 2016, Clinical Microbiology Reviews.
[277] T. Tahara,et al. Spectroscopic Tracking of Structural Evolution in Ultrafast Stilbene Photoisomerization , 2008, Science.
[278] M. Manos,et al. Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting , 2014, Digestive Diseases and Sciences.
[279] S. Zeuzem,et al. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. , 2011, Journal of hepatology.
[280] H. Alter,et al. HCV natural history: the retrospective and prospective in perspective. , 2005, Journal of hepatology.
[281] D. Lamarre,et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. , 2000, Bioorganic & medicinal chemistry letters.
[282] R. Cortese,et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. , 1998, Biochemistry.
[283] R. Gordon,et al. The design of potent and stable benzisothiazolone inhibitors of human leukocyte elastase , 1995 .
[284] M. Kozal,et al. Hepatitis C protease and polymerase inhibitors in development. , 2008, AIDS patient care and STDs.
[285] Dirk Calcoen,et al. What does it take to produce a breakthrough drug? , 2015, Nature Reviews Drug Discovery.
[286] A. Perelson,et al. Modeling HCV kinetics under therapy using PK and PD information , 2009, Expert opinion on drug metabolism & toxicology.
[287] Harold S Margolis,et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. , 2006, Gastroenterology.
[288] Xiaohong Liu,et al. Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent , 2015, PloS one.
[289] Jun Yu,et al. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. , 2014, World journal of gastroenterology.
[290] K. Chayama,et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.
[291] W. Groutas,et al. Potential mechanism-based inhibitors of proteolytic enzymes , 1992 .
[292] X. Forns,et al. An interferon-free antiviral regimen for HCV after liver transplantation. , 2014, The New England journal of medicine.
[293] C. Rice,et al. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro , 1995, Journal of virology.
[294] B. Beno,et al. Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase. , 2012, Bioorganic & medicinal chemistry letters.
[295] O. Weiland,et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study , 2014, Gut.
[296] J. Pawlotsky,et al. The non‐structural 5A protein of hepatitis C virus , 1999, Journal of viral hepatitis.
[297] A. Butt,et al. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[298] T. Berg,et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.
[299] Steven R. LaPlante,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.
[300] A. Flaxman,et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.
[301] Mark Harris,et al. Hepatitis C virus NS5A: tales of a promiscuous protein. , 2004, The Journal of general virology.
[302] J. G. Taylor,et al. GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study , 2016, Journal of viral hepatitis.
[303] E. Clercq. Current race in the development of DAAs (direct-acting antivirals) against HCV. , 2014 .
[304] Patricia Hurter,et al. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus , 2011, Nature Biotechnology.
[305] P. Shi,et al. Anti-infectives: can cellular screening deliver? , 2011, Current opinion in chemical biology.
[306] H. Nar,et al. Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease. , 2014, Journal of medicinal chemistry.
[307] V. de Lédinghen,et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. , 2015, JAMA.
[308] R Benigni,et al. Quantitative structure-activity relationships of mutagenic and carcinogenic aromatic amines. , 2000, Chemical reviews.
[309] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[310] M. Harris,et al. Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on! , 2015, The Journal of general virology.
[311] Martin Poirier,et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. , 2004, Journal of medicinal chemistry.
[312] A. Good,et al. HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies. , 2013, Bioorganic & medicinal chemistry letters.
[313] C. Rice,et al. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites , 1993, Journal of virology.
[314] C. Trépo,et al. Hepatitis: After HCV cure, HBV cure? , 2015, Nature Reviews Gastroenterology &Hepatology.
[315] P. Easterbrook,et al. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature , 2016, Journal of viral hepatitis.
[316] H. Toyoda,et al. Changes in hepatitis C virus genotype distribution in Japan , 2014, Epidemiology and Infection.
[317] M. Heim. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end , 2013, Nature Reviews Immunology.
[318] J. Lemm,et al. Specific Inhibition of Bovine Viral Diarrhea Virus Replicase , 2003, Journal of Virology.
[319] J. Lemm,et al. Development of a Cell-Based High-Throughput Specificity Screen Using a Hepatitis C Virus-Bovine Viral Diarrhea Virus Dual Replicon Assay , 2005, Antimicrobial Agents and Chemotherapy.
[320] R. Bartenschlager,et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions , 1993, Journal of virology.
[321] K. Reddy,et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. , 2015, Journal of hepatology.
[322] P. Simmonds,et al. Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.
[323] S. Das,et al. The in vivo and in vitro genotoxicity of aromatic amines in relationship to the genotoxicity of benzidine. , 1992, Mutation research.
[324] N. Meanwell,et al. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. , 2014, Journal of medicinal chemistry.
[325] B. Edlin,et al. Can hepatitis C be eradicated in the United States? , 2014, Antiviral research.
[326] F. Lichtenberg. The effect of new drug approvals on HIV mortality in the US, 1987-1998. , 2003, Economics and human biology.
[327] Hakan Gunaydin,et al. Stacking with No Planarity? , 2016, ACS medicinal chemistry letters.
[328] C. Rice,et al. Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.
[329] D. Lamarre,et al. Peptide-based inhibitors of the hepatitis C virus serine protease. , 1998, Bioorganic & medicinal chemistry letters.